CND Life Sciences, a Scottsdale, AZ-based medical technology company, raised an additional $1m in venture financing from Top Corner Capital.
The round, which brought the amount raised in Series Seed 3 funding to $4.5M and $12.5M in total to date, saw participation from existing investors as well as new investors.
Led by CEO Rick Morello, CND develops and commercializes skin-based tests to help clinicians across the country accurately diagnose and treat neurologic disorders such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and peripheral neuropathies. The company’s Syn-One test, a commercially available test that can identify abnormal alpha-synuclein aggregation through a skin biopsy, is powered by technology licensed from Beth Israel Deaconess Medical Center in Boston.
The company intends to use the funds to accelerate the commercialization of Syn-One with nearly 700 neurologist clinician customers in over 40 states and collaborations with biopharmaceutical companies.
FinSMEs
06/04/2023